Pembrolizumab (Keytruda®), in combination with axitinib (Inlyta®), is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 29/07/2019 |
| Rapid review completed | 23/08/2019 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with axitinib compared with the current standard of care. |